Errors occurred in the Clinical Practice Guideline article by Hampl SE et al, titled “Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity” published in the February 2023 issue of Pediatrics (2023;151(2):e2022060640; doi:10.1542/peds.2022-060640).
The online article has been corrected.
Reference #505 read: 505. Jebeile H, Gow ML, Baur LA, Garnett SP, Paxton SJ, Lister NB. Association of pediatric obesity treatment, including a dietary component, with change in depression and anxiety: a systematic review and meta-analysis. JAMA Pediatr. 2019;173(11):e192841–e192841.
This should have read: 505. Jebeile H, Gow ML, Baur LA, Garnett SP, Paxton SJ, Lister NB. Treatment of obesity, with a dietary component, and eating disorder risk in children and adolescents: a systematic review with meta-analysis. Obes Rev. 2019;20(9):1287–1298.
In Supplemental Information 2-docx file, Appendix 3, A.2.a, Frequency of Retesting for Prediabetes and T2DM, the text read: Pediatricians and other PHCPs may repeat testing for prediabetes and T2DM in 12 months, if HbA1c is 5.7 to <6.0% AND 1 or more risk factors for progression is present (severe obesity, weight gain, higher risk racial or ethnic groups, signs of insulin resistance such as acanthosis nigricans, or use of obesogenic psychotropic medications) (refer to KASs 3 and 3.1 for age and BMI category).
This should have read: Pediatricians and other PHCPs may repeat testing for prediabetes and T2DM in 12 months, if HbA1c is 5.7 to <6.0% AND 1 or more risk factors for progression is present (severe obesity, weight gain, racial or ethnic groups with higher prevalence of disease, signs of insulin resistance such as acanthosis nigricans, or use of obesogenic psychotropic medications) (refer to KASs 3 and 3.1 for age and BMI category).
In Supplemental Information 2-docx file, Appendix 3, B, Initial Management of Other Comorbidities, the table entry under Reevaluation Guidance for Abnormal glucose metabolism read: Pediatricians and other PHCPs may repeat testing for prediabetes and T2DM in 12 months, if HbA1c 5.7 to <6.0% AND 1 or more risk factors for progression is present (severe obesity, weight gain, higher-risk racial or ethnic groups, signs of insulin resistance such as acanthosis nigricans, or use of obesogenic psychotropic medications) (refer to KASs 3 and 3.1 for age and BMI category).
This should have read: Pediatricians and other PHCPs may repeat testing for prediabetes and T2DM in 12 months, if HbA1c 5.7 to <6.0% AND 1 or more risk factors for progression is present (severe obesity, weight gain, racial or ethnic groups with higher prevalence of disease, signs of insulin resistance such as acanthosis nigricans, or use of obesogenic psychotropic medications) (refer to KASs 3 and 3.1 for age and BMI category).
Comments